Section - Video Lectures

09. The Psychopharmacology of Parkinson’s Disease: Conclusions

Published on April 22, 2019 Expired on March 31, 2022

Gregory Pontone, M.D., M.H.S.

Division Chief of Aging, Behavioral, and Cognitive Neurology - University of Florida College of Medicine

Key Points

Depression in Parkinson’s is associated with increased physical disability and a loss of quality of life. It should be treated aggressively with psychotherapy and antidepressants.
Anxiety disorders occur in at least one-third of patients with Parkinson’s. They can occur episodically, manifesting during medication “off” periods.
Psychosis is a leading cause of hospitalization and nursing home placement in Parkinson’s and requires treatment with a select group of antipsychotics.
Impulse control disorders occur in up to 15% of patients treated with dopamine agonists and can have devastating consequences if unrecognized.

To unlock this video you need to become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Video (MP4)
Download Audio File (MP3)
Download Presentation File (PPTX)

Slides and Transcript

Slide 1 of 4

Conclusions.

The Psychopharmacology of Parkinson’s Disease: Conclusions Slide 1 of 4

Slide 2 of 4

Parkinson’s disease is a neurodegenerative condition which causes a combination of both motor and non-motor dysfunction. Psychiatric disorders occur at increased prevalence in Parkinson’s disease and are likely the result of a combination of biological, psychological and social changes resulting from the disease process.

The Psychopharmacology of Parkinson’s Disease: Conclusions Slide 2 of 4

Unlock this Video Lecture and earn 1.00 CMEs
Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in